Equities Analysts Set Expectations for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Analysts at Wedbush increased their Q1 2027 earnings estimates for shares of Biogen in a note issued to investors on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $4.13 per share for the quarter, up from their previous forecast of $3.85. Wedbush has a “Neutral” rating and a $135.00 price target on the stock. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q2 2027 earnings at $4.67 EPS and Q3 2027 earnings at $4.34 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The firm had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.32 billion. During the same quarter in the previous year, the company posted $5.28 EPS. Biogen’s revenue was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

A number of other analysts have also commented on the stock. HC Wainwright lifted their target price on shares of Biogen from $187.00 to $194.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Truist Financial assumed coverage on shares of Biogen in a report on Monday, July 21st. They set a “hold” rating and a $142.00 target price for the company. Piper Sandler lifted their target price on shares of Biogen from $115.00 to $118.00 and gave the stock a “neutral” rating in a report on Friday, September 12th. Jefferies Financial Group assumed coverage on shares of Biogen in a report on Thursday, September 25th. They set a “buy” rating and a $190.00 target price for the company. Finally, Wall Street Zen raised shares of Biogen from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 28th. Eleven analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $180.69.

Biogen Price Performance

BIIB opened at $143.00 on Friday. The company has a fifty day moving average price of $141.53 and a two-hundred day moving average price of $131.43. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. Biogen has a 52 week low of $110.04 and a 52 week high of $191.19. The firm has a market capitalization of $20.97 billion, a PE ratio of 13.67, a P/E/G ratio of 1.13 and a beta of 0.13.

Institutional Trading of Biogen

A number of large investors have recently made changes to their positions in the company. Norges Bank acquired a new position in Biogen in the 2nd quarter worth $284,358,000. AQR Capital Management LLC boosted its stake in Biogen by 153.6% in the 1st quarter. AQR Capital Management LLC now owns 1,368,842 shares of the biotechnology company’s stock worth $187,258,000 after purchasing an additional 829,150 shares during the period. OVERSEA CHINESE BANKING Corp Ltd boosted its stake in Biogen by 1,663.4% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 780,567 shares of the biotechnology company’s stock worth $106,813,000 after purchasing an additional 736,301 shares during the period. Orion Porfolio Solutions LLC boosted its stake in Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Biogen by 190.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock worth $78,415,000 after purchasing an additional 409,591 shares during the period. Institutional investors own 87.93% of the company’s stock.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the sale, the insider owned 5,772 shares in the company, valued at $770,850.60. This represents a 8.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is currently owned by corporate insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.